Logo image of AFMD

AFFIMED NV (AFMD) Stock Fundamental Analysis

NASDAQ:AFMD - Nasdaq - NL0015001ZQ0 - Common Stock - Currency: USD

0.1815  -0.1 (-34.95%)

After market: 0.1731 -0.01 (-4.63%)

Fundamental Rating

2

Taking everything into account, AFMD scores 2 out of 10 in our fundamental rating. AFMD was compared to 557 industry peers in the Biotechnology industry. AFMD may be in some trouble as it scores bad on both profitability and health. AFMD is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

AFMD had negative earnings in the past year.
In the past year AFMD has reported a negative cash flow from operations.
AFMD had negative earnings in each of the past 5 years.
In the past 5 years AFMD always reported negative operating cash flow.
AFMD Yearly Net Income VS EBIT VS OCF VS FCFAFMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of -175.10%, AFMD is doing worse than 87.32% of the companies in the same industry.
AFMD has a Return On Equity of -406.92%. This is in the lower half of the industry: AFMD underperforms 75.89% of its industry peers.
Industry RankSector Rank
ROA -175.1%
ROE -406.92%
ROIC N/A
ROA(3y)-59.16%
ROA(5y)-45.97%
ROE(3y)-93.94%
ROE(5y)-84.6%
ROIC(3y)N/A
ROIC(5y)N/A
AFMD Yearly ROA, ROE, ROICAFMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150

1.3 Margins

AFMD has a better Gross Margin (789.74%) than 100.00% of its industry peers.
AFMD's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for AFMD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 789.74%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.76%
GM growth 5Y-2.54%
AFMD Yearly Profit, Operating, Gross MarginsAFMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -500 -1K -1.5K

More info and screens

2

2. Health

2.1 Basic Checks

AFMD does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for AFMD remains at a similar level compared to 1 year ago.
Compared to 5 years ago, AFMD has more shares outstanding
The debt/assets ratio for AFMD is higher compared to a year ago.
AFMD Yearly Shares OutstandingAFMD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M
AFMD Yearly Total Debt VS Total AssetsAFMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

2.2 Solvency

AFMD has an Altman-Z score of -4.35. This is a bad value and indicates that AFMD is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of AFMD (-4.35) is comparable to the rest of the industry.
A Debt/Equity ratio of 0.35 indicates that AFMD is not too dependend on debt financing.
AFMD's Debt to Equity ratio of 0.35 is on the low side compared to the rest of the industry. AFMD is outperformed by 73.04% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.35
Debt/FCF N/A
Altman-Z -4.35
ROIC/WACCN/A
WACC6.81%
AFMD Yearly LT Debt VS Equity VS FCFAFMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M -100M 150M

2.3 Liquidity

A Current Ratio of 1.93 indicates that AFMD should not have too much problems paying its short term obligations.
AFMD's Current ratio of 1.93 is on the low side compared to the rest of the industry. AFMD is outperformed by 76.79% of its industry peers.
AFMD has a Quick Ratio of 1.93. This is a normal value and indicates that AFMD is financially healthy and should not expect problems in meeting its short term obligations.
AFMD's Quick ratio of 1.93 is on the low side compared to the rest of the industry. AFMD is outperformed by 75.36% of its industry peers.
Industry RankSector Rank
Current Ratio 1.93
Quick Ratio 1.93
AFMD Yearly Current Assets VS Current LiabilitesAFMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

More info and screens

4

3. Growth

3.1 Past

AFMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 42.15%, which is quite impressive.
Looking at the last year, AFMD shows a very negative growth in Revenue. The Revenue has decreased by -95.39% in the last year.
Measured over the past years, AFMD shows a very negative growth in Revenue. The Revenue has been decreasing by -19.00% on average per year.
EPS 1Y (TTM)42.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.25%
Revenue 1Y (TTM)-95.39%
Revenue growth 3Y-33.67%
Revenue growth 5Y-19%
Sales Q2Q%-92.1%

3.2 Future

The Earnings Per Share is expected to grow by 11.18% on average over the next years. This is quite good.
Based on estimates for the next years, AFMD will show a very strong growth in Revenue. The Revenue will grow by 35.57% on average per year.
EPS Next Y40.97%
EPS Next 2Y28.77%
EPS Next 3Y19.02%
EPS Next 5Y11.18%
Revenue Next Year-81.84%
Revenue Next 2Y-23.09%
Revenue Next 3Y14.98%
Revenue Next 5Y35.57%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
AFMD Yearly Revenue VS EstimatesAFMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M
AFMD Yearly EPS VS EstimatesAFMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -50 -100 -150 -200

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AFMD. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AFMD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AFMD Price Earnings VS Forward Price EarningsAFMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AFMD Per share dataAFMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4

4.3 Compensation for Growth

AFMD's earnings are expected to grow with 19.02% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.77%
EPS Next 3Y19.02%

More info and screens

0

5. Dividend

5.1 Amount

AFMD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AFFIMED NV

NASDAQ:AFMD (5/19/2025, 8:00:00 PM)

After market: 0.1731 -0.01 (-4.63%)

0.1815

-0.1 (-34.95%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-02 2025-05-02/amc
Earnings (Next)06-09 2025-06-09
Inst Owners22.64%
Inst Owner Change-21.07%
Ins Owners6.01%
Ins Owner ChangeN/A
Market Cap2.76M
Analysts84
Price Target12.24 (6643.8%)
Short Float %6.49%
Short Ratio0.05
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4.56%
Min EPS beat(2)-10.88%
Max EPS beat(2)1.75%
EPS beat(4)3
Avg EPS beat(4)4.52%
Min EPS beat(4)-10.88%
Max EPS beat(4)14.22%
EPS beat(8)4
Avg EPS beat(8)1.65%
EPS beat(12)7
Avg EPS beat(12)6.57%
EPS beat(16)8
Avg EPS beat(16)-11.38%
Revenue beat(2)0
Avg Revenue beat(2)-90.72%
Min Revenue beat(2)-92.4%
Max Revenue beat(2)-89.04%
Revenue beat(4)0
Avg Revenue beat(4)-85.87%
Min Revenue beat(4)-92.4%
Max Revenue beat(4)-74.24%
Revenue beat(8)2
Avg Revenue beat(8)-47.19%
Revenue beat(12)4
Avg Revenue beat(12)-23.39%
Revenue beat(16)7
Avg Revenue beat(16)-15.7%
PT rev (1m)0%
PT rev (3m)-11.76%
EPS NQ rev (1m)-5.91%
EPS NQ rev (3m)-5.91%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)-83.93%
Revenue NQ rev (3m)-83.93%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.78
P/FCF N/A
P/OCF N/A
P/B 0.14
P/tB 0.14
EV/EBITDA N/A
EPS(TTM)-5.18
EYN/A
EPS(NY)-2.73
Fwd EYN/A
FCF(TTM)-5.77
FCFYN/A
OCF(TTM)-5.73
OCFYN/A
SpS0.07
BVpS1.28
TBVpS1.28
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -175.1%
ROE -406.92%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 789.74%
FCFM N/A
ROA(3y)-59.16%
ROA(5y)-45.97%
ROE(3y)-93.94%
ROE(5y)-84.6%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.76%
GM growth 5Y-2.54%
F-Score1
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0.35
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 15.61%
Cap/Sales 60.89%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.93
Quick Ratio 1.93
Altman-Z -4.35
F-Score1
WACC6.81%
ROIC/WACCN/A
Cap/Depr(3y)175.27%
Cap/Depr(5y)145.6%
Cap/Sales(3y)18.76%
Cap/Sales(5y)12.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)42.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.25%
EPS Next Y40.97%
EPS Next 2Y28.77%
EPS Next 3Y19.02%
EPS Next 5Y11.18%
Revenue 1Y (TTM)-95.39%
Revenue growth 3Y-33.67%
Revenue growth 5Y-19%
Sales Q2Q%-92.1%
Revenue Next Year-81.84%
Revenue Next 2Y-23.09%
Revenue Next 3Y14.98%
Revenue Next 5Y35.57%
EBIT growth 1Y42.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-8.45%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y25.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y24.28%
OCF growth 3YN/A
OCF growth 5YN/A